-$0.52 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter

Equities research analysts expect that Zymeworks Inc (NYSE:ZYME) will post earnings of ($0.52) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Zymeworks’ earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.52). Zymeworks posted earnings of ($0.83) per share during the same quarter last year, which would indicate a positive year over year growth rate of 37.3%. The firm is scheduled to report its next earnings results on Tuesday, May 7th.

On average, analysts expect that Zymeworks will report full-year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($3.13) to ($1.94). For the next year, analysts expect that the company will report earnings of ($2.87) per share, with EPS estimates ranging from ($4.04) to ($1.69). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Zymeworks.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Wednesday, March 6th. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.19. The firm had revenue of $28.93 million for the quarter, compared to the consensus estimate of $65.00 million. Zymeworks had a negative return on equity of 23.17% and a negative net margin of 68.95%.

Several research firms have recently commented on ZYME. Zacks Investment Research upgraded Zymeworks from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Friday, March 29th. Raymond James set a $29.00 price objective on Zymeworks and gave the stock an “outperform” rating in a report on Thursday, March 14th. TheStreet upgraded Zymeworks from a “d” rating to a “c-” rating in a report on Friday, January 11th. Finally, ValuEngine upgraded Zymeworks from a “hold” rating to a “buy” rating in a report on Monday, January 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.43.

ZYME opened at $16.05 on Friday. The stock has a market capitalization of $514.00 million, a PE ratio of -12.74 and a beta of 1.48. Zymeworks has a 12 month low of $10.72 and a 12 month high of $29.00.

In related news, major shareholder Eli & Co Lilly sold 250,000 shares of the firm’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $16.00, for a total value of $4,000,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ali Tehrani sold 3,000 shares of the firm’s stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $16.24, for a total value of $48,720.00. The disclosure for this sale can be found here. 4.80% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can grew its stake in shares of Zymeworks by 17.9% in the fourth quarter. Bank of Montreal Can now owns 4,380 shares of the company’s stock worth $64,000 after purchasing an additional 665 shares during the last quarter. K.J. Harrison & Partners Inc boosted its position in Zymeworks by 25.0% during the 4th quarter. K.J. Harrison & Partners Inc now owns 15,000 shares of the company’s stock valued at $219,000 after acquiring an additional 3,000 shares in the last quarter. Point72 Asset Management L.P. boosted its position in Zymeworks by 15.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 115,000 shares of the company’s stock valued at $1,806,000 after acquiring an additional 15,000 shares in the last quarter. SG Americas Securities LLC bought a new stake in Zymeworks during the 4th quarter valued at approximately $225,000. Finally, Acadian Asset Management LLC boosted its position in Zymeworks by 35.1% during the 4th quarter. Acadian Asset Management LLC now owns 113,399 shares of the company’s stock valued at $1,667,000 after acquiring an additional 29,468 shares in the last quarter. 28.37% of the stock is currently owned by institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.

Recommended Story: Technical Analysis

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.